• Most Popular
  • Most Shared

Biogen says Tysabri goals "difficult" to achieve

BOSTON
Fri Feb 6, 2009 9:47am EST

BOSTON (Reuters) - Biogen Idec Inc backed off its previous forecast that 100,000 patients would be on its multiple sclerosis drug Tysabri by the end of 2010 and reported a new case of the brain disease PML.

Health

Biogen Chief Executive Jim Mullen said on a conference call with investors that it will be "difficult" to achieve its original 100,000 projection. The company also announced a new case of the potentially deadly brain infection progressive multifocal leukoencephalopathy, or PML.

Concerns over PML have curbed growth in sales of Tysabri.

(Reporting by Toni Clarke; Editing by Derek Caney)
Health


More from Reuters

Photo

Honda expands airbag recall as more Toyotas probed

TOKYO/DETROIT (Reuters) - Honda Motor Co said it would recall another 440,000 cars around the world for faulty airbags as rival Toyota Motor Corp faced further probes over its largest-ever safety crisis. | Video

» More Top News
Chairman of the Federal Reserve Ben Bernanke testifies before the Senate Banking, Housing and Urban Affairs Committee on Capitol Hill in Washington July 22, 2009. REUTERS/Kevin Lamarque
John Kemp:

The Fed needs a new storyline

It's irrelevant whether the Fed sells its assets back to the market. What matters is whether and when it's prepared to raise rates.  Commentary 

Economy
A worker drives a Toyota Motor Corp's newly assembled Prius hybrid vehicle onto a trailer near the company's plant in Toyota, central Japan February 9, 2010.REUTERS/Yuriko Nakao
Reuters Breakingviews:

Toyota's troubles in overdrive

The cost of Toyota's recall nightmare is nothing compared to the price of fixing its battered reputation.  Commentary 

Autos